Osteonecrosis of the Jaw in a Patient Treated with Denosumab and Temsirolimus

Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies

“…Within our selection, a total of 49 articles have been compiled in relation to osteonecrosis of the jaws [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22], two articles in relation to lesions in the oral mucosa [4,23], two with oral infections [24,25], and, finally, one article reporting a case of exudative erythema multiforme [26] (EEM) associated with the use of biological therapies.…”

“…Of the total of 49 articles related to osteonecrosis of the jaws, 14 cases were collected that refer to bevacizumab [10,[27][28][29][30][31][32][33][34][35][36][37][38][39], eight cases to sunitinib [17][18][19][20][21][22]29,39], six cases to denosumab [10][11][12][13][14] and everolimus [29,[39][40][41][42][43], five cases to rituximab [5,[11][12][13][14], four cases to temsirolimus [14,26,29,34], three cases referred to sorafenib [19,29,33] and aflibercept [44][45][46], two cases related to trastuzumab and pertuzumab [15,…”